HER2-Positive Breast Cancer | Topics

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer
February 24, 2021

The PHERGain II trial will investigate the treatment of patients with early HER2-positive breast cancer using a chemotherapy-free treatment approach of trastuzumab plus pertuzumab.

Relapsed/Refractory HER2+ Metastatic Breast Cancer
February 15, 2021

Recommendations for managing 2 patient cases specific to HER2-positive metastatic breast cancer and optimizing therapy for specific patient populations within the HER2-positive space based on emerging treatments and changes to standards of care.

Margetuximab Plus Chemo Improves PFS Versus Trastuzumab/Chemo in ERBB2+ Advanced Breast Cancer
February 05, 2021

Results from the phase 3 SOPHIA trial demonstrated that margetuximab plus chemotherapy had an acceptable safety profile which was comparable to that observed with trastuzumab plus chemotherapy.